Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SQ 109

Next Previous
X
Search
Drug Profile

SQ 109

Alternative Names: NSC 722041; SQ109

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Sequella
  • Developer Infectex; Ludwig-Maximilians-University; Sequella
  • Class Anti-inflammatories; Antibacterials; Antifungals; Antituberculars; Antiulcers; Ethylenediamines; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Tuberculosis
  • Preclinical Leishmaniasis
  • No development reported Duodenal ulcer; Helicobacter infections; Mycobacterial infections; Mycoses
  • Discontinued Crohn's disease

Most Recent Events

  • 13 Jun 2024 Preclinical trials in Leishmaniasis in USA (PO)
  • 13 Jun 2024 Pharmacodynamics data from preclinical studies in Leishmaniasis presented at ASM Microbe 2024 (ASMM-2024)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Tuberculosis in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top